Genetic variants of homocysteine metabolism and multiple sclerosis: A case–control study

• Published in: Neuroscience letters 2014-03, Vol.562, p.75-78
• Main Authors: Ineichen, Benjamin V., Keskitalo, Salla, Farkas, Melinda, Bain, Nadja, Kallweit, Ulf, Weller, Michael, Klotz, Luisa, Linnebank, Michael
• Format: Article
• Language: English
• Subjects: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase - genetics; Adult; Case-Control Studies; Cystathionine beta-synthase; Cystathionine beta-Synthase - genetics; Female; Folate; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homocysteine; Homocysteine - metabolism; Humans; Male; Methionine - genetics; Methionine - metabolism; Methylenetetrahydrofolate Reductase (NADPH2) - genetics; Middle Aged; Multiple sclerosis; Multiple Sclerosis - genetics; Multiple Sclerosis - metabolism; Polymorphism, Genetic; Reduced folate carrier 1; S-adenosylmethionine; S-Adenosylmethionine - genetics
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/j.neulet.2014.01.008

•Enzymatic variants of methionine metabolism are associated with development of MS.•Two genetic variants of methionine pathway were associated with MS age of onset.•Methionine metabolism can be manipulated by supplementation of vitamins.•We propose novel preventive and therapeutic strategies for MS. Methylenetetrahydrofolate reductase (MTHFR) is necessary for the synthesis of methionine and S-adenosylmethionine, which is necessary for CNS (re-)myelination. The MTHFR variant c.1298A>C was associated with the development of relapsing remitting multiple sclerosis (RRMS) in a German population. This study aimed at analyzing whether further genetic variants of methionine metabolism are associated with the development or the clinical course of RRMS. Therefore, genomic DNA of 147 serial German RRMS patients and 147 matched healthy controls was genotyped for five polymorphic variants of methionine metabolism. Statistical analyses were performed using multivariate binary and linear regression analyses. We show that the insertion allele of cystathionine beta-synthase (CBS) c.844_855ins68bp and the G-allele of reduced folate carrier 1 (RFC1) c.80G>A were associated with an earlier age of onset of MS, suggesting gene-dose effects (median age of onset in years: 25-26-32; standardized regression coefficient beta: 0.216; p=0.030, and 29-31-35 years; beta: 0.282; p=0.005, respectively). Conclusively, mutant variants of CBS and RFC1 may be associated with the age of RRMS onset. Since methionine metabolism can be manipulated by supplementation of vitamins and amino acids, our data provide a rationale for novel ideas of preventive and therapeutic strategies in RRMS.